


2-27-04



VPI/SW/006 FWC DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Examiner : Not Yet Assigned
Group Art Unit : Not Yet Assigned
Applicants : Rolland Dolle et al.
Appln. No. : 10/668 475 Confirmation No.: 2933
Filed : September 22, 2003
For : PYRIDAZINES AS INTERLEUKIN-1 β CONVERTING
ENZYME INHIBITORS

EXPRESS MAIL CERTIFICATION

"Express Mail" mailing label number EV270263463US .

Date of Deposit February 25, 2004 .

I hereby certify that this transmittal letter and the other papers and fees identified in this transmittal letter as being transmitted herewith are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and are addressed to the Hon. Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia, 22313-1450.


Lillian Garcia

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

New York, New York
February 25, 2004

TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information Disclosure Statement in the above-identified application. This Statement is submitted:

- ☐ within three months of the application filing date;
- ☒ more than three months from the application filing date but before the mailing date of the first Office Action on the merits.


In accordance with 37 C.F.R. § 1.97(b)(3), submission of this Statement requires no fee. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)
Min Wang (Reg. No. 51,303)
Attorneys for Applicants

c/o FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
50th Floor
New York, New York 10020
Tel.: (212) 596-9000



TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT

Transmitted herewith is an Information Disclosure Statement in the above-identified application. This Statement is submitted:

- ☐ within three months of the application filing date;
- ☒ more than three months from the application filing date but before the mailing date of the first Office Action on the merits.

In accordance with 37 C.F.R. § 1.97(b)(3), submission of this Statement requires no fee. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,

James F. Haley, Jr. (Reg. No. 27,794)
Min Wang (Reg. No. 51,303)
Attorneys for Applicants

c/o FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
50th Floor
New York, New York 10020
Tel.: (212) 596-9000



VPI/SW/006 FWC DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned
Group : Not Yet Assigned
Applicants : Roland Dolle et al.
Application No. : 10/668,475
Confirmation No.: 2933
Filed : September 22, 2003
For : PYRIDAZINES AS INTERLEUKIN-1 β CONVERTING ENZYME
INHIBITORS

New York, New York
February 25, 2004

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants make of record the
following documents, copies of which are submitted herewith:*

UNITED STATES PATENT DOCUMENTS

4,215,109	issued July 29, 1980
4,590,194	issued May 20, 1986
4,710,499	issued December 1, 1987
5,055,451	issued October 8, 1991

* A completed Form PTO-1449 listing these documents is attached hereto.



5,081,145 issued January 14, 1992
5,418,233 issued May 23, 1995
6,121,266 issued September 19, 2000

FOREIGN PATENT DOCUMENTS

EP 0 519 748 A2 published December 23, 1992
EP 0 537 696 A1 published April 21, 1993
EP 193 249 published September 3, 1986
WO 91/15577 published October 17, 1991

OTHER REFERENCES

Dornow et al., "Synthesen von Pyrazolo[3.4-c]pyridazinen", Chem. Ber., 97, 3349-3353 (1964).

Wermuth et al., "3-Aminopyridazine Derivatives with Atypical Antidepressant, Serotonergic, and Dopaminergic Activities", J. Med. Chem., 32, 528-537 (1989).

Applicants request that the cited documents be (1) fully considered by the Examiner during the course of examination of this application, and that the Examiner (2) initialize form PTO-1449 to indicate consideration of the documents and (3) return a copy of Form PTO-1449, as considered and initialed by the Examiner, to the undersigned with the next communication. Applicants also request that the cited documents be printed on any patent issuing from this application.

Respectfully submitted,

James F. Haley, Jr. (Reg. No. 27,794)

Min Wang (Reg. No. 51,303)

Attorneys for Applicants

c/o FISH & NEAVE

Customer No. 1473

1251 Avenue of the Americas

New York, NY 10020-1104

Tel.: (212) 596-9000

Fax.: (212) 596-9090

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
VPI/SW/006 FWC DIVAPPLN. NO.
10/668,475APPLICANT
Roland Dolle et al.CONFIRMATION
NO.
2933FILING DATE
September 22, 2003GROUP
Not Yet AssignedINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,215,109	07/29/80	Ruhenstroth-Bauer et al.	424	177	
	4,590,194	05/20/86	Leshner et al.	514	247	
	4,710,499	12/1/87	Wermuth et al.	514	247	
	5,055,451	10/8/91	Krantz et al.	514	19	
	5,081,145	01/14/92	Guindon et al.	514	419	
	5,418,233	05/23/95	Linz et al.	514	247	
	6,121,266	09/19/00	Dolle et al.	514	252.03	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0 519 748 A2	12/23/92	EPO				
	EP 0 537 696 A1	04/21/93	EPO				
	EP 0 193 249	09/03/86	EPO				
	WO 91/15577	10/17/91	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Dornow et al., "Synthesen von Pyrazolo[3.4-c]pyridazinen", <u>Chem. Ber.</u> , 97, 3349-3353 (1964).


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail:
EV270263463US

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
VPI/SW/006 FWC DIVAPPLN. NO.
10/668,475INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Roland Dolle et al.CONFIRMATION
NO.
2933FILING DATE
September 22, 2003GROUP
Not Yet Assigned

	Wermuth et al., "3-Aminopyridazine Derivatives with Atypical Antidepressant, Serotonergic, and Dopaminergic Activities", J. Med. Chem., 32, 528-537 (1989).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.